Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
2mg |
|
||
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
Purity: = 98.76%
Liraglutide, a Glucagon-like Peptide 1 (GLP-1) analog, is a potent agonist of the Glucagon-like Peptide 1 receptor. It is prescribed to patients with type 2 diabetes mellitus who do not respond to metformin as an anti-hyperglycemic agent and additional therapy.
Targets |
GLP-1 receptor
|
---|---|
ln Vitro |
Liraglutide may provide protection against endothelial cell dysfunction (ECD), an early abnormality in diabetic vascular disease, by attenuating the induction of plasminogen activator inhibitor type-1 (PAI-1) and vascular adhesion molecule (VAM) expression in human vascular endothelial cells (hVECs) in vitro. Research conducted in vitro indicates that stimulated expression of VAM and PAI-1 is inhibited by liraglutide in a GLP-1R-dependent manner[3].
|
ln Vivo |
In the ApoE-/-mouse model, vascular reactivity and immunohistochemical analysis are investigated in vivo. In mice given liraglutide, they show a marked improvement in endothelial function, an effect that is dependent on GLP-1R. Additionally, ligandomycin treatment decreases the expression of intercellular adhesion molecule-1 (ICAM-1) in the aortic endothelium and increases endothelial nitric oxide synthase (eNOS), both of which are reliant on the GLP-1R[3]. Liraglutide increases pancreatic b cell mass through enhanced proliferation, which lowers hyperglycemia in T2D mouse models[2].
|
Cell Assay |
In Nunclon cell culture dishes coated with gelatin and supplemented with Media-199 containing penicillin/streptomycin, 20% FCS, 20 µg/ml endothelial cell growth factor, and 20 µg/ml heparin, C11-STH cells are grown until confluence at 37°C. Under serum-free conditions, C11-STH cells are cultured with 100 nM liraglutide or 100 nM GLP-1 receptor antagonist exendin (9-39) alone, or with 10 ng/ml TNFα for 16 hours either in combination with liraglutide and/or exendin (9-39). Protein expression levels are measured using ELISA assays for VCAM-1 and ICAM-1 using conditioned medium from C11-STH cells.
|
Animal Protocol |
Athymic nude mice
300 μg/kg/day s.c. |
References |
Molecular Formula |
C172H265N43O51
|
---|---|
Molecular Weight |
3751.2020
|
Exact Mass |
3748.95
|
Elemental Analysis |
C, 55.07; H, 7.12; N, 16.06; O, 21.75
|
CAS # |
204656-20-2
|
Related CAS # |
Liraglutide-d8 triTFA; Liraglutide-13C5,15N tetraTFA
|
SequenceShortening |
HAEGTFTSDVSSYL-{N6-[N-(1-oxohexadecyl)-L-γ-Etamyl]-Glu}-GQAAKEFIAWLVRGRG
|
Appearance |
Solid powder
|
SMILES |
CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC6=CN=CN6)N)C(=O)O
|
InChi Key |
YSDQQAXHVYUZIW-QCIJIYAXSA-N
|
InChi Code |
InChI=1S/C172H265N43O51/c1-18-20-21-22-23-24-25-26-27-28-29-30-37-53-129(224)195-116(170(265)266)59-64-128(223)180-68-41-40-50-111(153(248)199-115(62-67-135(232)233)154(249)204-120(73-100-44-33-31-34-45-100)159(254)214-140(93(11)19-2)167(262)192-97(15)146(241)201-122(76-103-79-183-108-49-39-38-48-106(103)108)157(252)203-118(72-90(5)6)158(253)212-138(91(7)8)165(260)200-110(52-43-70-182-172(177)178)149(244)184-81-130(225)193-109(51-42-69-181-171(175)176)148(243)187-84-137(236)237)196-144(239)95(13)189-143(238)94(12)191-152(247)114(58-63-127(174)222)194-131(226)82-185-151(246)113(61-66-134(230)231)198-155(250)117(71-89(3)4)202-156(251)119(75-102-54-56-105(221)57-55-102)205-162(257)124(85-216)208-164(259)126(87-218)209-166(261)139(92(9)10)213-161(256)123(78-136(234)235)206-163(258)125(86-217)210-169(264)142(99(17)220)215-160(255)121(74-101-46-35-32-36-47-101)207-168(263)141(98(16)219)211-132(227)83-186-150(245)112(60-65-133(228)229)197-145(240)96(14)190-147(242)107(173)77-104-80-179-88-188-104/h31-36,38-39,44-49,54-57,79-80,88-99,107,109-126,138-142,183,216-221H,18-30,37,40-43,50-53,58-78,81-87,173H2,1-17H3,(H2,174,222)(H,179,188)(H,180,223)(H,184,244)(H,185,246)(H,186,245)(H,187,243)(H,189,238)(H,190,242)(H,191,247)(H,192,262)(H,193,225)(H,194,226)(H,195,224)(H,196,239)(H,197,240)(H,198,250)(H,199,248)(H,200,260)(H,201,241)(H,202,251)(H,203,252)(H,204,249)(H,205,257)(H,206,258)(H,207,263)(H,208,259)(H,209,261)(H,210,264)(H,211,227)(H,212,253)(H,213,256)(H,214,254)(H,215,255)(H,228,229)(H,230,231)(H,232,233)(H,234,235)(H,236,237)(H,265,266)(H4,175,176,181)(H4,177,178,182)/t93-,94-,95-,96-,97-,98+,99+,107-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,138-,139-,140-,141-,142-/m0/s1
|
Chemical Name |
(2S)-5-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]propanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-(hexadecanoylamino)-5-oxopentanoic acid
|
Synonyms |
NNC 90-1170; Liraglutide; NN 2211; NN-2211; NN2211; trade names: Saxenda; Victoza
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: ~100 mg/mL (~26.7 mM)
Water: ~100 mg/mL Ethanol: ~100 mg/mL |
---|---|
Solubility (In Vivo) |
5%DMSO + 40%PEG300 + 5%Tween 80 + 50%ddH2O: 5.0mg/ml (1.33mM) (Please use freshly prepared in vivo formulations for optimal results.)
|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 0.2666 mL | 1.3329 mL | 2.6658 mL | |
5 mM | 0.0533 mL | 0.2666 mL | 0.5332 mL | |
10 mM | 0.0267 mL | 0.1333 mL | 0.2666 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT02516657 | Active Recruiting |
Drug: Liraglutide | Type 1 Diabetes | University at Buffalo | May 2012 | Phase 3 |
NCT04529278 | Active Recruiting |
Drug: Liraglutide | Diabetes Mellitus, Type 2 Hemodialysis Obese |
Fondation Hôpital Saint-Joseph | January 18, 2021 | Phase 2 |
NCT04883346 | Active Recruiting |
Drug: Liraglutide | Obesity Status Post Sleeve Gastrectomy |
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
June 21, 2021 | Phase 2 |
NCT02344186 | Active Recruiting |
Drug: Liraglutide | Type 2 Diabetes | Temple University | May 2014 | Phase 4 |
NCT02944500 | Active Recruiting |
Drug: liraglutide Other: Placebo |
Obesity | Beth Israel Deaconess Medical Center |
November 2016 | Phase 4 |
Effects of long-term daily liraglutide treatment on glucose homeostasis. Cell Metab . 2016 Mar 8;23(3):541-6. td> |